1
|
Successful treatment with glecaprevir/pibrentasvir for chronic hepatitis C complicated by primary biliary cholangitis. Clin J Gastroenterol 2020; 13:896-901. [PMID: 32065362 DOI: 10.1007/s12328-020-01103-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/07/2020] [Accepted: 02/04/2020] [Indexed: 10/25/2022]
Abstract
BACKGROUND Cases of autoimmune liver diseases complicated with hepatitis C (HCV) infection have occasionally been reported. However, the efficacy and safety of direct acting antivirals for chronic hepatitis C (CHC) complicated with autoimmune liver diseases remain unclear. CASE REPORT A 74-year-old woman was referred to our hospital for an acute exacerbation of liver dysfunction. She had been diagnosed with CHC 10 years previously. Laboratory data showed elevated immunoglobulin G (IgG), and she was positive for antinuclear antibody (ANA), anti-mitochondrial M2 antibody, and HCV-RNA (genotype 2a). Liver biopsy revealed significant infiltration of lymphocytes and plasma cells in the portal triad, moderate interface hepatitis with mild bridging fibrosis, and chronic non-suppurative destructive cholangitis. She was diagnosed with chronic active hepatitis and primary biliary cholangitis (PBC). Combination therapy with glecaprevir/pibrentasvir (GLE/PIB) rapidly improved her serum transaminase and HCV-RNA levels. A sustained viral response was achieved 24 weeks after GLE/PIB. No adverse events were observed, and her IgG and ANA levels were normalized 6 months after GLE/PIB. The second liver biopsy performed 10 months after GLE/PIB demonstrated the remarkable improvement of active hepatitis. However, the findings suggesting PBC were remained and the AMA-M2 titer was decreased but positive at that time. CONCLUSION GLE/PIB is an effective and tolerated choice for the treatment in cases of CHC complicated by PBC.
Collapse
|
2
|
Bano N, Najam R. Histopathological and biochemical assessment of liver damage in albino Wistar rats treated with cytotoxic platinum compounds in combination with 5-fluorouracil. Arch Med Sci 2019; 15:1092-1103. [PMID: 31360204 PMCID: PMC6657249 DOI: 10.5114/aoms.2019.86064] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/25/2016] [Accepted: 04/20/2017] [Indexed: 12/12/2022] Open
Abstract
INTRODUCTION Chemotherapy-induced hepatotoxicity in cancer patients often results in cessation of therapy and prevents completion of the treatment plan. The entire pathological description and comparison of hepatic damage induced by oxaliplatin or cisplatin in combination with 5-fluorouracil (5-FU) is not adequately reported. This study reports histopathological assessment of hepatotoxicity of a non-tumor bearing organ in rats treated with 5-FU, oxaliplatin and cisplatin (CDDP). MATERIAL AND METHODS Changes in hepatic biochemical profile of 36 albino Wistar rats equally divided into different treatment groups with cisplatin, oxaliplatin, 5-FU, cisplatin plus 5-FU and oxaliplatin plus 5-FU were compared with a group of rats treated with normal saline (control group). At the end of treatments, hepatic tissues were taken for blinded histopathological assessment by light microscopy. RESULTS Serum glutamate pyruvate transaminase and serum glutamic-oxaloacetic transaminase levels were disrupted in rats treated with 5-FU alone and in combination with cisplatin or oxaliplatin. Hepatocellular injuries, e.g. sinusoidal dilatation, venular fibrosis and centrilobular vein injury induced by oxaliplatin were intensified in treatment groups also receiving 5-FU, manifested as massive architectural distortion, periportal fibrosis, hepatic cord degeneration and cystic lesions with demarcated margins. Hepatocellular degenerative sequence and abnormally dilated central hepatic vein was shown in the cisplatin plus 5-FU treatment group with hemorrhage and blood filled sinusoids. CONCLUSIONS Oxaliplatin-associated cystic lesions were intensified in rats treated with a combination of 5-FU and oxaliplatin.
Collapse
Affiliation(s)
- Nusrat Bano
- Department of Pharmacology, King Saud Bin Abdulaziz University For Health Sciences, Jeddah, Saudi Arabia
| | - Rahila Najam
- Department of Pharmacology, University of Karachi, Karachi, Saudi Arabia
| |
Collapse
|
3
|
Li J, Dou D, Li P, Luo W, Lv W, Zhang C, Song X, Yang Y, Zhang Y, Xu Y, Xiao F, Wei Y, Qin J, Li H, Yang X. PARP-1 serves as a novel molecular marker for hepatocellular carcinoma in a Southern Chinese Zhuang population. Tumour Biol 2017; 39:1010428317706914. [PMID: 28714367 DOI: 10.1177/1010428317706914] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
PARP-1 (poly(ADP-ribose) polymerase-1) plays an important role in tumorigenesis. Since its effects on different populations are varied, this study investigated the impact of PARP-1 on primary hepatocellular carcinoma in a Southern Chinese Zhuang population. We assessed the global PARP-1 messenger RNA expression in patients with hepatocellular carcinoma using The Cancer Genome Atlas dataset. Increased PARP-1 expression, related to alpha-fetoprotein level, was observed. The area under the receiver operating characteristic curve value was 0.833. Kaplan-Meier survival curves indicated that higher PARP-1 expression was not correlated with poorer overall survival and recurrence-free survival. In a Zhuang population, PARP-1 messenger RNA and protein levels were increased in the hepatocellular carcinoma tissue and its adjacent liver tissues as assessed by quantitative polymerase chain reaction, immunohistochemistry, and western blotting. Higher PARP-1 level was associated with a higher tumor stage (p < 0.05), without correlation with age, gender, smoking, drinking, tumor size, serum alpha-fetoprotein level, hepatitis B virus infection, metastasis, and invasion (p > 0.05). Further analysis suggested that H2AX, a PARP-1 protein interaction partner, was coordinated with PARP-1 in hepatocellular carcinoma tumorigenesis. Overall, some new characteristics of PARP-1 expression were noted in the Zhuang population. PARP-1 is a novel promising diagnostic marker for hepatocellular carcinoma in the Southern Chinese Zhuang population.
Collapse
Affiliation(s)
- Jiatong Li
- 1 Medical Scientific Research Center, Guangxi Medical University, Nanning, P.R. China
| | - Dongwei Dou
- 1 Medical Scientific Research Center, Guangxi Medical University, Nanning, P.R. China.,2 Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, P.R. China
| | - Ping Li
- 3 Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, P.R. China
| | - Wenqi Luo
- 3 Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, P.R. China
| | - Wenxin Lv
- 4 Department of Urology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, P.R. China
| | - Chengdong Zhang
- 5 School of Life Sciences, Fudan University, Shanghai, P.R. China
| | - Xiaowei Song
- 1 Medical Scientific Research Center, Guangxi Medical University, Nanning, P.R. China
| | - Yuan Yang
- 5 School of Life Sciences, Fudan University, Shanghai, P.R. China
| | - Yuening Zhang
- 1 Medical Scientific Research Center, Guangxi Medical University, Nanning, P.R. China
| | - Yanzhen Xu
- 1 Medical Scientific Research Center, Guangxi Medical University, Nanning, P.R. China
| | - Feifan Xiao
- 1 Medical Scientific Research Center, Guangxi Medical University, Nanning, P.R. China
| | - Yan Wei
- 3 Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, P.R. China
| | - Jian Qin
- 6 School of Public Health, Guangxi Medical University, Nanning, P.R. China
| | - Hongtao Li
- 1 Medical Scientific Research Center, Guangxi Medical University, Nanning, P.R. China
| | - Xiaoli Yang
- 1 Medical Scientific Research Center, Guangxi Medical University, Nanning, P.R. China
| |
Collapse
|